Lab21, bioMerieux, DiagnoCure sales and marketing update

bioMerieux's bioTheranostics Inc. subsidiary granted Lab21 exclusive rights to market the Theros CancerTYPE ID molecular cancer classifier in the U.K., Ireland and the Middle East. The test predicts cancer origin based on 92 genes. bioTheranostics will perform all sample testing in its CLIA-certified laboratory in San Diego, Calif. ...